

Atty. Docket No. PG3693USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Michael Birsha DAVIES et al.

Serial No.: 10/031,637

Art Unit: 3743

Filing Date: December 19, 2001

Examiner: Ali, Shumaya B.

For: *Medicament Carrier*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☐ Copies of the references are enclosed
- ☐ Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))
- ☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. ☒ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,
- whichever occurs first.
- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☒ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

MAR. 2. 2006 4:19PM

GLAXO WELLCOME

NO. 9277 P. 14

Atty. Docket No. PG3693USw

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☒ A duplicate copy of this paper is attached.

Respectfully Submitted,


James R. Riek
Attorney of Record
Registration No. 39,009

Date: March 2, 2006
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8022
Facsimile: (919) 483-7988

MAR. 2. 2006 4:19PM

GLAXO WELLCOME

NO. 9277 P. 15

Atty. Docket No. PG3693USw

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[X] A duplicate copy of this paper is attached.

Respectfully Submitted,


James A. Riek
Attorney of Record
Registration No. 39,009

Date: March 2, 2006
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8022
Facsimile: (919) 483-7988

MAR. 2. 2006 4:19PM

GLAXO WELLCOME

NO. 9277 P. 16

Page 1 of 1

FORM PTO-1449				SERIAL NO.		10/031,637	
INFORMATION DISCLOSURE STATEMENT				FILING DATE		December 19, 2001	
				APPLICANT		Michael Birsha Davies	
				GROUP		3743	
				EXAMINER		Ali, Shumaya B.	
				ATTORNEY DOCKET NO.		PG3693USw	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	103,012	05/1870	Not Available			
	2.	776,649	12/1904	Not Available			
	3.	895,527	08/1908	Not Available			
	4.	1,192,859	08/1916	Not Available			
	5.	1,476,682	12/1923	Not Available			
	6.	1,490,529	04/1924	Not Available			
	7.	2,197,845	04/1940	Not Available			
	8.	2,298,451	10/1942	Not Available			
	9.	2,399,000	04/1946	Not Available			
	10.	2,465,876	03/1949	Not Available			
	11.	2,598,823	06/1952	Not Available			
	12.	2,889,958	06/1959	Not Available			
	13.	2,989,212	06/1961	Not Available			
	14.	3,039,652	06/1962	Not Available			
	15.	3,107,782	10/1963	Not Available			
	16.	3,301,392	01/1967	Not Available			
	17.	3,338,400	08/1967	Not Available			
	18.	3,342,326	09/1967	Not Available			
	19.	3,482,733	12/1969	Not Available			
	20.	3,692,176	09/1972	TEMPLETON et al.			
	21.	3,856,142	12/1974	VASSALO			
	22.	3,967,761	07/1976	MELTON et al.			
	23.	4,373,631	02/1983	FRIESE et al.			
	24.	4,428,709	01/1984	PETERS			
	25.	4,444,310	04/1984	ODELL			
	26.	4,474,349	10/1984	LOECKLE			
	27.	5,590,645	01/1997	DAVIES			
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
Continue on page _____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							